Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 10, pp 3040–3045 | Cite as

Sentinel Node Lymph Node Surgery After Neoadjuvant Therapy: Principles and Techniques

  • Jennifer M. Racz
  • Abigail S. CaudleEmail author
Breast Oncology
  • 225 Downloads

Abstract

Surgical management of the axilla in breast cancer has been a topic of great interest. While sentinel lymph node biopsy (SLNB) is an established approach for patients undergoing surgical treatment as the first element of their care, there is continued debate regarding surgical management of the axilla in patients receiving neoadjuvant chemotherapy (NAC). In clinically node-negative patients, it has been debated whether or not SLNB should be performed before chemotherapy to accurately determine the clinical stage, or after chemotherapy, thus prioritizing the response to therapy and potentially minimizing axillary surgery. Node-positive patients have undergone axillary lymph node dissection in the past, however this paradigm has been challenged in recent years. Thus, surgeons must understand the importance of accurate axillary information both before and after NAC, and its role in multidisciplinary planning. We present a summary of the data surrounding axillary management in patients receiving NAC, and recommendations for surgical technique.

Notes

Disclosures

Jennifer M. Racz has no conflicts of interest or disclosures to declare. Abigail S. Caudle is supported by a National Institutes of Health Cancer Center Support grant (CA16672) and has received travel expenses for speaking engagements from EndoMag. She is also the Principal Investigator for research supported by EndoMag.

References

  1. 1.
    Sacre R. Clinical evaluation of axillary lymph nodes compared to surgical and pathological findings. Eur J Surg Oncol. 1986;12(2):169–73.PubMedGoogle Scholar
  2. 2.
    Krishnamurthy S, Sneige N, Bedi D, et al. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer. 2002;95(5):982–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Topal U, Punar S, Tasdelen I, Adim S. Role of ultrasound-guided core needle biopsy of axillary lymph nodes in the initial staging of breast carcinoma. Eur J Radiol. 2005;56(3):382–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients: a study of 115 cases with cytologic-histologic correlation. Cancer. 2008;114(2):89–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Tahir M, Osman K, Shabbir J, et al. Preoperative axillary staging in breast cancer-saving time and resources. Breast J. 2008;14(4):369–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Von Minckwitz G, Huang C, Mano M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.CrossRefGoogle Scholar
  7. 7.
    Masuda N, Lee S, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59.CrossRefPubMedGoogle Scholar
  8. 8.
    Hunt K, Yi M, Mittendorf E, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558–66.PubMedGoogle Scholar
  9. 9.
    van der Heiden-van der Loo M, de Munck L, Sonke G, et al. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: identification rate and influence on axillary treatment. Eur J Cancer. 2015;51(8):915–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Krag D, Anderson S, Julian T, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mamounas E, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694–702.CrossRefPubMedGoogle Scholar
  12. 12.
    van Deurzen C, Vriens B, Tian-Heijnan V, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45(18):3120–4.Google Scholar
  13. 13.
    Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.CrossRefGoogle Scholar
  14. 14.
    Nogi H, Uchida K, Mimoto R, et al. Long-term follow-up of node-negative breast cancer patients evaluated via sentinel node biopsy after neoadjuvant chemotherapy. Clin Breast Cancer. 2017;17(8):644–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Boughey J, McCall L, Ballman K, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):608–14.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Alvarado R, Yi M, Le-Petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012;19(10):3177–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Classe J, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27(5):726–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Newman E, Sabel M, Nees A, et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Sug Oncol. 2007;14(10):2946–52.CrossRefGoogle Scholar
  19. 19.
    Balch G, Mithani S, Richards K, Beauchamp R, Kelley M. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol. 2003;10(6):616–21.CrossRefPubMedGoogle Scholar
  20. 20.
    Boughey J, Suman V, Mittendorf E, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–64.CrossRefGoogle Scholar
  22. 22.
    Classe J, Loaec C, Gimberques P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173(2):343–52.CrossRefPubMedGoogle Scholar
  23. 23.
    Boughey J, Ballman K, Symmans W, et al. Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0–T4, N1–2) who receive neoadjuvant chemotherapy—results from a prospective trial—ACOSOG Z1071 (Alliance) [poster]. Presented at the thirty-seventh annual CTRC-AACR San Antonio breast cancer symposium; 9–13 December 2014; San Antonio, TX. http://www.sabcs.org/Portals/SABCS/Documents/2014SABCSCall4Abstracts.pdf. Accessed 12 July 2019.
  24. 24.
    Boughey J, Ballman K, Hunt K, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015;33(30):3368–93.CrossRefGoogle Scholar
  25. 25.
    Schwentner L, Helms G, Neklijudova V, et al. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy: results from the multi-center SENTINA trial. Breast. 2017;31:202–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Boughey J, Ballman K, Le-Petross H, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802–7.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Caudle A, Yang W, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cabıoğlu N, Karanlık H, Kangal D, et al. Improved false-negative rates with intraoperative identification of clipped nodes in patients undergoing sentinel lymph node biopsy after neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(10):3030–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Diego E, McAuliffe P, Soran A, et al. Axillary staging after neoadjuvant chemotherapy for breast cancer: a pilot study combining sentinel lymph node biopsy with radioactive seed localization of pre-treatment positive axillary lymph nodes. Ann Surg Oncol. 2016;23(5):1549–53.CrossRefPubMedGoogle Scholar
  30. 30.
    Nguyen T, Kiejen T, Glazebrook K, Boughey J. Localizing the clipped node in patients with node-positive breast cancer treated with neoadjuvant chemotherapy: early learning experience and challenges. Ann Surg Oncol. 2017;24(10):3011–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Siso C, de Torres J, Esqueva-Colmenarejo A, et al. intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA trial): a new tool to guide the excision of the clipped node after neoadjuvant treatment. Ann Surg Oncol. 2018;25(3):784–91.CrossRefPubMedGoogle Scholar
  32. 32.
    Simons J, Van Nijnatten T, Van der Pol C, Luiten E, Koppert L, Smidt M. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2019;269(3):432–42.CrossRefPubMedGoogle Scholar
  33. 33.
    Caudle A, Yang W, Mittendorf E, et al. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015;150(2):137–43.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Choy N, Lipson J, Porter C, et al. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. Ann Surg Oncol. 2015;22(2):377–82.CrossRefPubMedGoogle Scholar
  35. 35.
    Natsiopoulos I, Intzes S, Liappis T, et al. Axillary lymph node tattooing and targeted axillary dissection in breast cancer patients who presented as cN + before neoadjuvant chemotherapy and became cN0 after treatment. Clin Breast Cancer. 2019;19(3):208–215.CrossRefPubMedGoogle Scholar
  36. 36.
    Park S, Koo J, Kim G, et al. Feasibility of charcoal tattooing of cytology-proven metastatic axillary lymph node at diagnosis and sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients. Cancer Res Treat. 2018;50(3):801–12.CrossRefPubMedGoogle Scholar
  37. 37.
    Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261(2):378–82.CrossRefPubMedGoogle Scholar
  38. 38.
    van Nijnatten T, Simons J, Smidt M, et al. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study. Clin Breast Cancer. 2017;17(5):399–402.CrossRefPubMedGoogle Scholar
  39. 39.
    Kliniken Essen-Mitte. Prospective, multicenter, registry trial to evaluate utilization frequency and feasibility of targeted axillary dissection (TAD) after needle biopsy and clip placement in early breast cancer with clinically affected lymph nodes (NCT03102307). www.clinicaltrials.gov. Accessed 16 Jun 2019.
  40. 40.
    Institut Cancerologie de l’Ouest. Sentinel lymph node after neoadjuvant chemotherapy in breast carcinoma (GANEA-3) [NCT03630913]. www.clinicaltrials.gov. Accessed 12 July 2019.
  41. 41.
    Derby Hospitals NHS Foundation Trust. Pre-ATNEC—preoperative tattooing of biopsied axillary node in breast cancer and correlation to sentinel lymph nodes in breast cancer patients (NCT03640819). www.clinicaltrials.gov. Accessed 16 Jun 2019.
  42. 42.
    Hartmann S, Reimer T, Gerber B, Stubert J, Stengel B, Stachs A. Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy. Eur J Surg Oncol. 2018;44(9):1307–11.CrossRefPubMedGoogle Scholar
  43. 43.
    Barrio A, Mamtani A, Edelweiss M, et al. How often is treatment effect identified in axillary nodes with a pathologic complete response after neoadjuvant chemotherapy? Ann Surg Oncol. 2016;23(11):3475–80.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Caudle A, Kuerer H, Krishnamurthy S, et al. Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: a prospective registry study. Cancer. 2019;125(3):365–73.CrossRefPubMedGoogle Scholar
  45. 45.
    Shin K, Caudle A, Kuerer H, et al. Radiologic mapping for targeted axillary dissection: needle biopsy to excision. AJR Am J Roentgenol. 2016;207(6):1372–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Woods R, Camp M, Durr N, Harvey S. A review of options for localization of axillary lymph nodes in the treatment of invasive breast cancer. Acad Radiol. 2019;26(6):805–19.CrossRefPubMedGoogle Scholar
  47. 47.
    Moo T, Edelweiss M, Hajiyeva S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol. 2018;25(6):1488–94.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of SurgeryMayo ClinicRochesterUSA
  2. 2.Department of Breast Surgical OncologyUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations